Siglec-15 has been shown to be expressed in osteosarcoma cells and may inhibit proliferation in osteosarcoma through the signal transducer and activator of transcription 3 (STAT3/Bcl-2) pathway, while inducing apoptosis and pyroptosis22. Here, BCL2 is linked to osteosarcoma.